Lv6
2330 积分 2022-05-09 加入
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
18小时前
已完结
Recent advances in therapeutic targeting of the KRAS pathway in cancer
18天前
已完结
Combinatorial strategies to target RAS-driven cancers
18天前
已完结
Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review
24天前
已完结
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells
3个月前
已完结
Unlocking the promise of RAS inhibition in pancreatic cancer
3个月前
已完结
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
3个月前
已完结
Direct RAS inhibitors turn 10
4个月前
已完结
皖公网安备34019202002308
